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ABSTRACT
Background Subacute sclerosing panencephalitis is 
a progressive neurodegenerative disorder caused by a 
latent and mutant measles virus which is extremely rare 
in developed countries. The lack of effective treatments 
leads to the research of other anti- inflammatory and 
neuroprotective treatments.
Case Here we present a case of a 17- year- old patient 
affected by subacute sclerosing panencephalitis who 
manifest a dramatic improvement in neurological and 
general clinical conditions, as well as an arrest in the 
progression of demyelinating process in the central 
nervous system, after the beginning of a high ratio 
ketogenic diet.
Conclusions Given its anti- inflammatory, antioxidant and 
metabolic effects, we believe that ketogenic diet utilisation 
could be a rational approach, can be considered a safe 
add- on therapy, carrying on with only a minimal risk of 
adverse effects or interactions.
INTRODUCTION
Subacute sclerosing panencephalitis (SSPE) 
is a progressive neurodegenerative disorder, 
occurring with a median latency of 9.5 years 
after measles infection and causing wide-
spread demyelination of the central nervous 
system.1
SSPE are expected in 4–11 cases for every 
100 000 cases of measles, increasing to 18 for 
every 100 000 cases if infection occurs in early 
childhood.2 In Italy, during 2017–2018, 8078 
new cases of measles infection were ascer-
tained, 1627 more in 2019.3
Although vaccination prevents SSPE and 
30%–35% of patients may benefit from 
therapy4–6 in terms of slower progression, 
prolonged survival or clinical improvement,1 
currently there is no definitive cure. Hence 
the need of further therapeutic options.
We report a case of SSPE, with typical elec-
troencephalogram (EEG) and magnetic 
resonance (MR) patterns,7 8 treated with a 




A 17- year- old girl experienced two loss of 
consciousness in September 2019, followed 
by progressive mood changes, irritability and 
a decline in her academic performance. In 
December 2019, she developed involuntary 
jerks in her upper limbs, widespread stiffness 
with abnormal limb postures, progressive 
decline in functional abilities, with the need 
of assistance to get dressed and climb stairs. 
She soon developed daily crying jags and 
insomnia. Her menstrual cycle was altered 
and amenorrhoea occurred.
Following this, she experienced a rapid 
decrease of visual acuity and was no longer 
able to read. At our first evaluation, in January 
2020, we observed cognitive slowing, speech 
impoverishment, motor impairment and gait 
unsteadiness. She needed help when walking 
and changing position. Spasticity of the upper 
limbs, more severe in the right arm, cervical 
dystonia and dystonic posturing of right limb 
were present. Myoclonic jerks involving arms, 
especially the right one, occurred at regular 
intervals.
Laboratory analyses and neurophysiological 
assessment
Oligoclonal bands type III on cerebrospinal 
fluid (CSF) and increased anti- measles IgG 
antibody titre in CSF (10 589 UI) and serum 
(22 038 UI), were found. PCR for measles was 
negative in CSF, serum and nasopharyngeal 
swab.
The mother revealed that the patient had 
contracted measles infection at 2 months old, 
before the age of mandatory vaccination.
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The EEG showed the characteristic periodic Rader-
mecker complexes, in 1:1 relation with the myoclonic 
jerks. During sleep, Radermecker complexes were always 
present, but the associated jerks disappeared.
MRI
The patient underwent a brain MR examination with 
a 1.5- Tesla system, which revealed the presence of 
T2- weighted and fluid- attenuated inversion recovery 
(FLAIR) asymmetrical, confluent white matter hyper-
intensities (figure 1A,B) with high signal on apparent 
diffusion coefficient (ADC) maps of diffusion- weighted 
images sequence (figure 1C) involving both parietal lobes 
and the splenium of corpus callosum. A focal lesion char-
acterised by diffusion restriction was detected in the left 
putamen. No contrast enhancement was seen. Magnetic 
resonance spectroscopy in the white matter of the right 
parietal lobe showed decreased N- acetyl- aspartate (NAA) 
with substantially normal Choline/Creatine (Cho/Cr) 
ratio.
Based on clinical history, neurological examination, 
EEG, MR images and anti- measles IgG antibody titres, the 
patient was diagnosed with SSPE.9
Treatments
Symptomatic treatment of the myoclonic jerks was 
attempted with administration of piracetam, levetirac-
etam, valproate, clonazepam, lacosamide and lamo-
trigine, all without clear effects.
Beneficial, although transient, effect on the intensity of 
jerks was observed with repetitive transcranial magnetic 
stimulation.
Cervical dystonia was treated with three botulinum 
neurotoxin injection sessions, in association with phar-
macological treatment with trihexyphenidyl.
Antiviral therapy with methisoprinol 3000 mg/die and 
ribavirin 800 mg/die was immediately started after diag-
nosis, without significant results.
Ketogenic diet
In absence of any clinical improvement, at the end of 
February 2020, a normocaloric 3:1 ketogenic diet was 
started, with rapid induction through fasting and subse-
quent switch to 4:1 ketogenic ratio after 1 month. All the 
administered drugs were in sugar- free formulation. At 
the end of April, medium chain triglyceride oil was added 
(30 mL/die). Thereafter, the patient achieved stable 
levels of capillary β-hydroxybutyrate (3.8–4.6 mmol/L).
Dietary treatment was well tolerated and no side effects 
were observed, except for reduction of 11 kg in body 
weight, before stabilisation. Although globally reduced, 
the myoclonic jerks became prevalent in the right arm.
In May, after three administrations of steroids for 
retinal angiography, blood ketone level decreased 
to 1.8 mmol/L, with severe worsening of motor and 
behavioural symptoms.
A month later, ketosis reached stable levels of 
4.5–5 mmol/L, with progressive improvement of cogni-
tive and motor functions.
Clinical follow-up
After 1 year, the myoclonic jerks are still present especially 
in the upper left limb and inferior right limb, but they 
appear reduced in amplitude and frequency. Dystonic 
posturing is no longer present.
Figure 1 A- C show typical confluent and asymmetrical white matter hyperintensities on fluid- attenuated inversion recovery 
(FLAIR) (A) and turbo spin- echo- T2- weighted (TSE- T2W) (B) involving both parietal lobes with prevalence on the right side. The 
splenium of the corpus callosum is also involved. On the apparent diffusion coefficient maps (C) there is no evidence of diffusion 
restriction of the white matter.
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The patient is now able to dress and wash herself, walk 
and climb stairs without aid. Cognitive performance has 
improved and she is now able to read, follow classes and 
use a smartphone and notebook. Irritability and crying 
jags are now infrequent. Sleep quality has improved, 
insomnia has disappeared and night arm stiffness has 
been reduced. Finally, a regular menstrual cycle has 
resumed.
MR follow-up
The patient underwent five additional MR examina-
tions: basal and 21, 38, 69 and 219 days after the first 
observation.
In April 2020, a small focal lesion appeared in the right 
putaminal nucleus while the left putaminal lesion resulted 
more hyperintense in T2W and FLAIR sequences.
For each brain MR examination, we have also calculated 
an ADC ratio of the white matter of the right parietal lobe 
using the homolateral frontal horn of the lateral ventricle 
as internal reference, with the following results in the five 
consecutive MR sessions: 0.37 – 0.39 – 0.41 – 0.48 – 0.42.
DISCUSSION
In SSPE, an altered cellular response results in virus silent 
persistence and later reactivation in the central nervous 
system. Perivascular infiltration of inflammatory cells, 
demyelination and oxidative damage are described in the 
earlier phases of the disease.4
Glutamate transport alteration and lipid peroxidation 
follow this stage⁠, in which inflammation becomes less 
evident and cortical atrophy ensues, with neurofibrillary 
tangles of abnormally hyperphosphorylated tau protein 
accumulation and neuronal loss.1
Considering the pathogenesis of SSPE, KD utilisation 
could be a rational approach, given its anti- inflammatory, 
antioxidant and metabolic effects.10 KD also modulates 
glutamatergic neurotransmission.11 ⁠
Two cases of SSPE treated with KD have been previously 
described. In the first, utilisation of a 4:1 KD regimen in 
a young boy resulted in the resolution of the myoclonic 
jerks after 2 weeks of treatment, lasting for 3 months, 
before loss of effect and disease progression.12 ⁠
In the second, a 2:1 ketogenic diet, with an average 
2.2 mmol/L blood ketone level, caused improvement in 
cognition and physical abilities after 1 month of diet and 
resolution of the myoclonic jerks after 11 months. More-
over, in this case a dramatic improvement in EEG pattern 
was reported.13
Neither of them has been studied with ADC ratio.
In our case, we observed global clinical improvement, 
stability of EEG pattern and progressive reduction of 
myoclonus and dystonia after the achievement of stable 
ketosis (June 2020).
While motor improvements could be attributed also to 
the other treatments, the arrest of SSPE progression is 
more reasonably due to the anti- inflammatory and neuro-
protective action of KD.
The worsening of both motor and behavioural symp-
toms during the transient loss of ketosis, caused by 
steroids, supports the significant role of KD.
Even if 5%–6% of patients may experience sponta-
neous prolonged remission,6 14 we think that the use of 
KD may have modified the natural course of disease in 
this patient. Considering the complete ineffectiveness of 
methisoprinol and ribavirin before KD and contradictory 
and scarce data regarding their efficacy in literature,1 5 6 
we believe that their role has been very limited.
The bilateral, asymmetrical confluent T2W and FLAIR 
hyperintensities involving the white matter of both pari-
etal lobes, splenium of corpus callosum as well as the 
abnormalities in the basal ganglia regions are in accor-
dance with previous observations.8 15 The NAA/Cho and 
NAA/Cr ratios observed in the white matter are consis-
tent with a severe neuronal loss.8
While the new right putaminal lesion appeared before 
stable ketosis, the hyperintensities of the occipital bilat-
eral white matter manifested a considerable slowing in 
progression in ADC ratio between the fourth (April 2020) 
and the fifth (September 2020) MR examination, which 
was the period of time when our patient achieved and 
maintained stable and high levels of blood ketones.
CONCLUSIONS
These days, SSPE is very rare in developed countries. 
Due to the lack of effective treatment, the disease usually 
progresses to death, occurring mostly within 3 years.14 To 
the best of our knowledge, this is the first case in whom 
the effects of KD have been extensively described from a 
clinical, neurophysiological and neuroradiological point 
of view.
While vaccination remains fundamental in SSPE 
prevention, a multimodal treatment approach may be 
considered.
Ketogenic diet can be considered a safe add- on therapy, 
carrying on with only a minimal risk of adverse effects or 
interactions.
A longer period of observation is necessary to confirm 
if effects of KD on neuroinflammation and neurodegen-
eration are able to modify the course of this devastating 
disease.
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